Charles River Laboratories International
 
 
 
 
公司概覽
業務類別 Diagnostics & Research
業務概覽 Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
公司地址 251 Ballardvale Street, Wilmington, MA, USA, 01887
電話號碼 +1 781 222-6000
傳真號碼 --
公司網頁 https://www.criver.com
員工數量 19700
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Mark Mintz Corporate Executive Vice President and Chief Information Officer & Global Shared Services -- 18/02/2026
Ms. Birgit Girshick Chief Operating Officer and Director 美元 760.96K 09/01/2026
Mr. Joseph W. LaPlume Corporate Executive Vice President, Corporate Development and Strategy 美元 570.17K 18/02/2026
Ms. Shannon M. Parisotto Corporate Executive Vice President -- 18/02/2026
Mr. James C. Foster Chairman of the Board, President and Chief Executive Officer 美元 1.55M 09/01/2026
Mr. Michael Gunnar Knell Corporate Senior Vice President and Chief Accounting Officer 美元 448.12K 18/02/2026
Ms. Victoria L. Creamer Corporate Executive Vice President 美元 553.75K 18/02/2026
Mr. Glenn G. Coleman, C.P.A. Corporate Executive Vice President and Chief Financial Officer -- 18/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Steven K. Barg Independent Director 31/03/2026
Mr. Mark Joseph Enyedy Independent Director 31/03/2026
Mr. Paul W. Graves Independent Director 31/03/2026
Ms. Birgit Girshick Chief Operating Officer and Director 09/01/2026
Mr. George Llado, Sr Independent Director 31/03/2026
Ms. Reshema Kemps-Polanco Independent Director 31/03/2026
Mr. Abraham Ceesay Director 31/03/2026
Mr. James C. Foster Chairman of the Board, President and Chief Executive Officer 09/01/2026
Dr. Martin W. Mackay, PhD Independent Director 09/01/2026
Dr. Nancy C. Andrews, M.D.,PhD Independent Director 31/03/2026
Dr. Craig B. Thompson,M.D. Independent Director 31/03/2026
Ms. Virginia M. Wilson Independent Director 31/03/2026
 
所屬ETF (更新日期: 02/05/2026 02:48)
代號 名稱 佔比% 持有日期
SCHXSchwab US Large-Cap ETF™0.10%29/04/2026
JHMMJHancock Multifactor Mid Cap ETF0.10%29/04/2026
FMDEFidelity Enhanced Mid Cap ETF0.09%29/04/2026
IUSViShares Core S&P US Value ETF0.08%29/04/2026
DFUVDimensional US Marketwide Value ETF0.08%29/04/2026
SPHBInvesco S&P 500® High Beta ETF0.08%29/04/2026
THQabrdn Healthcare Opportunities0.08%31/03/2026
HQHabrdn Healthcare Investors0.08%28/02/2026
VTVanguard Total World Stock ETF0.08%31/03/2026
IWBiShares Russell 1000 ETF0.07%29/04/2026
TMSLT. Rowe Price Small-Mid Cap ETF0.07%29/04/2026
FNDXSchwab Fundamental U.S. Large CompanyETF0.06%29/04/2026
SCHBSchwab US Broad Market ETF™0.06%29/04/2026
VONVVanguard Russell 1000 Value ETF0.06%31/03/2026
KOMPStt Strt®SPDR®S&PKenshoNwEcosComposETF0.06%29/04/2026
BBHVanEck Biotech ETF0.06%29/04/2026
THWabrdn World Healthcare0.06%31/03/2026
IYHiShares US Healthcare ETF0.05%29/04/2026
SCHVSchwab US Large-Cap Value ETF™0.05%29/04/2026
IXJiShares Global Healthcare ETF0.05%28/04/2026
  1   2    3    4    5    6    7    8    9    10    11    12  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.